Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Biocure Technology
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses, including ATR-002 (zapnometinib), a first-in-class,...
Brand Name : ATR-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Biocure Technology
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
Details : RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support ...
Brand Name : ATR-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 13, 2021
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ATR-002 is an oral small molecule, in a dose escalation study demonstrated excellent safety and tolerability and the observed pharmacokinetic profile supports the intended once-daily regime for the upcomi...
Brand Name : ATR-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2020
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
Details : Atriva’s lead product ATR-002 candidate is the only host-targeted antiviral specifically developed to treat respiratory infections with RNA viruses, such as influenza virus and the novel SARS-CoV-2.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2020
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?